TARGETING MALARIA WITH PRECISION: INNOVATIONS IN ANTIBODY-BASED INTERVENTIONS

 

Malaria, a potentially fatal illness brought on by Plasmodium parasites, is mainly transmitted by mosquito bites. The World Health Organization estimates that in 2023, there were about 263 million cases of malaria and 597,000 fatalities. Plasmodium falciparum is the most prevalent of the five Plasmodium species that cause malaria, and it is found in African nations where the disease is most prevalent. In these areas, the majority of deaths from malaria occur in children under five. Safe and efficient countermeasures are needed to lessen this enormous burden.

New vaccinations and the creation of anti-malarial monoclonal antibodies (mAbs) are two recent developments in malaria prevention. Early clinical trials have demonstrated the safety and effectiveness of these mAbs in preventing P. falciparum infections. These monoclonal antibodies (mAbs) target the parasite's sporozoite stage in order to kill it before it infects the liver and stop it from progressing to blood-stage malaria, which is fatal and causes severe disease.

Advancements in Anti-Malarial mAbs

The circumsporozoite protein (PfCSP), a protein on the sporozoite surface, is the target of the most promising anti-malarial monoclonal antibodies that have been tested so far. The central repeat region of PfCSP, which is also a part of the current malaria vaccines, is where these antibodies attach. The researchers took a new method by isolating human mAbs that were generated in response to entire sporozoites as opposed to just particular parasite components. In a mouse model, they subsequently assessed these mAbs' capacity to neutralize sporozoites. The most effective mAb among those tested was MAD21-101, which protected mice from P. falciparum infection.

Unlike the core repeat region that current vaccines target, MAD21-101 binds to a conserved epitope on PfCSP called pGlu-CSP. Only after a particular developmental stage in the sporozoite's life cycle does the pGlu-CSP epitope become visible. Despite this, it is still easily accessible on the surface of sporozoites, which makes it a good target for triggering a defense mechanism.

Interestingly, since the epitope is not present in the current formulations of malaria vaccines, mAbs that target pGlu-CSP would not affect their effectiveness. This presents a big benefit because these antibodies might protect at-risk infants who haven't been vaccinated yet but might get one in the future.

Implications and Future Directions

Malaria prevention has advanced significantly with the identification of MAD21-101 and its binding to the pGlu-CSP epitope. In areas where malaria is endemic, this novel class of monoclonal antibodies has the potential to be used in conjunction with current malaria vaccinations, especially to protect susceptible groups like infants. These results may also help direct the creation of novel vaccines that use pGlu-CSP to boost protection against P. falciparum.

The study emphasizes the necessity of further investigation into the efficacy and activity of the recently discovered antibody class and epitope. The methodology employed in this study may also be utilized to create defenses against other infections, opening the door for further significant advancements in the prevention of infectious diseases.

REFERENCES:

Dacon, Cherrelle, Re’em Moskovitz, Kristian Swearingen, Lais Da Silva Pereira, Yevel Flores-Garcia, Maya Aleshnick, Sachie Kanatani et al. "Protective antibodies target cryptic epitope unmasked by cleavage of malaria sporozoite protein." Science 387, no. 6729 (2025): eadr0510.

Image source: https://www.asiatiquebiotech.com/product-page/anti-malaria-pldh-pf-mab-for-conjugation